Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 8c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q2 EPS of ($0.57), $0.08 worse than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Yum! Brands completes Pizza Hut sale to LongRange for $1.5B
• GoPro to merge with Starman Optical in $285M recapitalization deal